Physician profile
John J Cush
NPI 1265492680
$3,696,835.55
in general payments reported to CMS, 2019-2025
20 companies · $606K in 2025
The $606K reported for 2025 was more than what 99% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135K · 2020: $311K · 2021: $508K · 2022: $732K · 2023: $687K · 2024: $718K · 2025: $606K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $975K · Grant: $910K · Consulting Fee: $82K · Travel and Lodging: $25K · Honoraria: $14K · Food and Beverage: $4,079 · Education: $53.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $975,386.93 |
| Grant | $909,500.00 |
| Consulting Fee | $82,326.92 |
| Travel and Lodging | $25,234.86 |
| Honoraria | $14,048.33 |
| Food and Beverage | $4,079.16 |
| Education | $53.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,350,049.89 | 2019-2025 | Rinvoq, Humira |
| Novartis Pharmaceuticals Corporation | $788,540.64 | 2019-2025 | Ilaris |
| E.R. Squibb & Sons, L.L.C. | $397,601.23 | 2019-2024 | |
| Ucb, INC. | $48,445.21 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $34,169.92 | 2019-2025 | |
| Genentech USA, INC. | $29,154.02 | 2019-2025 | Actemra |
| Janssen Scientific Affairs, LLC | $16,016.08 | 2022-2025 | Tremfya |
| Amgen INC. | $7,119.73 | 2022-2023 | Otezla, Tavneos |
| Gilead Sciences, INC. | $6,635.95 | 2019 | |
| Eli Lilly and Company | $5,600.00 | 2020 | |
| Lilly USA, LLC | $5,360.25 | 2019-2021 | |
| Ucb Sa | $3,750.00 | 2023 | Cimzia |
| Genzyme Corporation | $2,842.33 | 2019 | |
| Genentech, INC. | $812.82 | 2025 | |
| Assertio Therapeutics, INC. | $354.72 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $249.59 | 2024-2025 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $52.77 | 2023 | |
| Medline Industries LP | $46.96 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.44 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.